Indication
Hyperlipoproteinemias
2 clinical trials
3 products
Clinical trial
A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying TherapiesStatus: Active (not recruiting), Estimated PCD: 2024-07-30
Product
PlaceboProduct
ObicetrapibProduct
VupanorsenClinical trial
A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of Vupanorsen (PF-07285557) in Statin-Treated Participants With DyslipidemiaStatus: Completed, Estimated PCD: 2021-09-29